Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSCS NASDAQ:PETV NASDAQ:PSTV NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSCSHeartSciences$3.92-5.8%$3.81$2.36▼$6.47$4.50M2.57125,392 shs31,184 shsPETVPetVivo$0.80+2.6%$0.76$0.29▼$0.98$19.42M0.8420,458 shs27,186 shsPSTVPlus Therapeutics$0.37-3.0%$0.34$0.16▼$2.31$19.53M0.6910.69 million shs7.24 million shsXAIRBeyond Air$3.26+0.6%$3.73$2.90▼$13.52$13.99M0.2281,787 shs175,071 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSCSHeartSciences+5.32%-27.40%+11.83%+25.87%+4.00%PETVPetVivo+1.30%0.00%+11.43%+40.36%+42.08%PSTVPlus Therapeutics+18.21%+9.12%+24.11%-41.85%-78.66%XAIRBeyond Air0.00%-16.92%-43.16%-32.39%-71.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSCSHeartSciences2.2125 of 5 stars3.52.00.00.02.20.01.3PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics1.7138 of 5 stars3.32.00.00.02.50.00.6XAIRBeyond Air4.6283 of 5 stars3.75.00.03.53.20.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSCSHeartSciences 3.00Buy$13.00231.63% UpsidePETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$10.832,816.11% UpsideXAIRBeyond Air 3.40Buy$23.67625.97% UpsideCurrent Analyst Ratings BreakdownLatest HSCS, XAIR, PETV, and PSTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025XAIRBeyond AirD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/17/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.006/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$9.006/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.505/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSCSHeartSciences$20K211.68N/AN/A$11.16 per share0.35PETVPetVivo$1.05M18.56N/AN/A($0.03) per share-26.67PSTVPlus Therapeutics$5.82M3.26N/AN/A($1.52) per share-0.24XAIRBeyond Air$3.70M3.81N/AN/A$3.32 per share0.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSCSHeartSciences-$6.61M-$7.48N/AN/AN/AN/A-178.80%-109.28%8/4/2025 (Estimated)PETVPetVivo-$10.95M-$0.42N/A∞N/A-902.82%-4,813.07%-281.78%8/12/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)XAIRBeyond Air-$46.62M-$15.80N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)Latest HSCS, XAIR, PETV, and PSTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PSTVPlus Therapeutics-$0.12N/AN/AN/A$1.08 millionN/A8/5/2025Q1 2026XAIRBeyond Air-$0.08N/AN/AN/A$1.75 millionN/A8/4/2025N/AHSCSHeartSciences-$2.51N/AN/AN/AN/AN/A6/17/2025Q4 2025XAIRBeyond Air-$2.80-$1.80+$1.00-$0.09$1.39 million$1.15 million5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSCSHeartSciencesN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSCSHeartSciencesN/A1.020.83PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A1.031.03XAIRBeyond Air0.643.202.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSCSHeartSciences17.24%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipHSCSHeartSciences1.80%PETVPetVivo10.84%PSTVPlus Therapeutics3.76%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSCSHeartSciences101.08 million1.06 millionNot OptionablePETVPetVivo2024.27 million19.06 millionNot OptionablePSTVPlus Therapeutics2051.00 million49.08 millionNot OptionableXAIRBeyond Air704.32 million3.48 millionOptionableHSCS, XAIR, PETV, and PSTV HeadlinesRecent News About These CompaniesD. Boral Capital Initiates Coverage of Beyond Air (XAIR) with Buy RecommendationJuly 18 at 9:16 AM | msn.comBeyond Air, Inc. (XAIR) - Yahoo FinanceJuly 12, 2025 | finance.yahoo.comBeyond Air (NASDAQ:XAIR) Stock Price Down 7.1% - What's Next?July 11, 2025 | americanbankingnews.comBeyond Air Implements Reverse Stock Split for Nasdaq ComplianceJuly 10, 2025 | tipranks.comBeyond Air Inc.June 26, 2025 | barrons.comHere's Why Beyond Air (XAIR) Could be Great Choice for a Bottom FisherJune 26, 2025 | zacks.comBeyond Air (XAIR) Q4 2025 Earnings Call TranscriptJune 21, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Call TranscriptJune 20, 2025 | msn.comBeyond Air posts narrower-than-feared Q4 loss, shares surge 15%June 18, 2025 | investing.comBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 17, 2025 | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17, 2025 | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17, 2025 | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16, 2025 | quiverquant.comQBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16, 2025 | globenewswire.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSCS, XAIR, PETV, and PSTV Company DescriptionsHeartSciences NASDAQ:HSCS$3.92 -0.24 (-5.77%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.06 (+1.66%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.PetVivo NASDAQ:PETV$0.80 +0.02 (+2.56%) As of 03:38 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.37 -0.01 (-3.00%) Closing price 04:00 PM EasternExtended Trading$0.36 -0.01 (-3.63%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Beyond Air NASDAQ:XAIR$3.26 +0.02 (+0.62%) Closing price 04:00 PM EasternExtended Trading$3.32 +0.06 (+1.84%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
